KLOW

Home › Research › KLOW

View KLOW in the AxYn range →

Snapshot

Chemistry and make-up

KLOW is Glow plus KPV: four separate peptides co-lyophilised in one vial. As with Glow there is no official standard ratio; the widely marketed example is 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV = 80 mg total. A reputable supplier should define and lock its own spec rather than accept “KLOW” as standardised.

The fourth component:

• KPV is the tripeptide Lys-Pro-Val, corresponding to residues 11-13 of alpha-melanocyte-stimulating hormone (α-MSH). Formula C16H30N4O4, MW ~342.4, PubChem CID 125672 (verified via PubChem REST, 2026-07-30) [B]. It is small, has no copper and no disulphide, and is the anti-inflammatory piece of the blend. Note that a plain name search for “KPV” on PubChem returns an unrelated non-peptide compound, so the CoA must key off the sequence Lys-Pro-Val, not the three-letter shorthand.

All the Glow-level QC points carry over (see `glow.md`): GHK-Cu copper complexation must be confirmed; BPC-157 salt form stated; and TB-500 identity resolved (fragment ~889 Da vs full Tβ4 ~4963 Da) by MS. KLOW therefore requires four identities and four loads to be verified independently, which is the hardest CoA burden in the range.

What it is studied for (evidence)

No blend-specific human or animal trial data exists for KLOW. Evidence is the sum of the four single-component literatures; combining them does not create new evidence. Point to the components:

• GHK-Cu: ECM/collagen signalling, antioxidant, wound-healing; mostly in vitro/cosmetic [A/D].
• BPC-157: large rodent repair body of work, minimal human data (see `bpc-157.md`) [A].
• TB-500 / Tβ4: actin-sequestering, migration/wound-healing mechanism; human data mainly topical ocular Tβ4 (see `tb-500.md`) [A].
• KPV (α-MSH 11-13): anti-inflammatory tripeptide that enters cells and inhibits NF-κB / IKK signalling; preclinical evidence for reduced severity of DSS- and TNBS-induced colitis in mice and protection of intestinal epithelial barriers (Gastroenterology, PepT1-mediated KPV uptake01852-5/abstract); α-MSH barrier protection, PMC5245816) [A]. No human clinical trials confirm these effects; evidence is animal/cell only.
• Marketing claims vs data: KLOW is sold as an upgraded “repair + anti-inflammatory” stack. No controlled study shows synergy or any human outcome for the combination. KPV’s own evidence is preclinical.
• Human clinical status: none for the blend.

Handling, format and stability

Supplied lyophilised; reconstituted with bacteriostatic water for research handling (no dosing guidance here). Store lyophilised cold, protected from light; reconstituted material is cold-chain dependent. Four peptides with different degradation profiles share one vial, and the redox-active copper in GHK-Cu sits alongside oxidation-sensitive residues (Tβ4 methionine), so finished-blend stability data is more informative than component data alone.

Regulatory and trade status

• UK/EU RUO: research use only; not a medicine. Keep listings/emails strictly research-use.
• WADA (sport): prohibited. Contains TB-500 (Tβ4), banned at all times under S2; BPC-157 adds S0 exposure. KLOW inherits WADA-prohibited status (WADA Prohibited List) [B]. KPV is not the reason for the ban but does not remove it.
• US: on 23 July 2026 the PCAC voted to recommend BPC-157, TB-500 and KPV (each 8-6, 1 abstention) for the 503A bulks list, over FDA staff objection; these are advisory recommendations only, not rules, and still need FDA rulemaking. GHK-Cu is on a separate track, removed from the interim 503A lists in April 2026 and awaiting a later PCAC consult (before Feb 2027). The blend itself is not an approved product; AxYn sells it strictly research use only.
• Customs: four-component blends attract the most identity/load scrutiny.

Sources

• [B] PubChem: KPV CID 125672 (C16H30N4O4, MW ~342.4); GHK-Cu CID 165429100; BPC-157 CID 9941957; Tβ4 CID 45382195 — https://pubchem.ncbi.nlm.nih.gov
• [A] KPV reduces intestinal inflammation via PepT1 uptake, *Gastroenterology* — https://www.gastrojournal.org/article/S0016-5085(07)01852-5/abstract
• [A] α-MSH/KPV protects intestinal epithelial barrier (PMC5245816) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245816/
• [B] WADA Prohibited List (S2 covers TB-500/Tβ4) — https://www.wada-ama.org/en/prohibited-list
• [A] Component evidence: see `bpc-157.md`, `tb-500.md`, and `glow.md`
• [D] Vendor blend listings/ratios (source of the 50/10/10/10 example and dosing charts we do not use)

Plain summary

KLOW (KGlow) is Glow plus KPV: a four-peptide blend commonly sold as an 80 mg vial (50 mg GHK-Cu + 10 mg each of BPC-157, TB-500 and KPV), with no standard ratio, so a reputable supplier should define and lock its own. There is no human or blend-specific trial evidence for KLOW; KPV adds a genuine but preclinical, animal-only anti-inflammatory rationale, and the blend is banned in sport (WADA S2) because it contains TB-500. The CoA burden is the heaviest in the range: it must independently prove the identity and load of all four peptides, including resolving the TB-500 fragment-vs-full-Tβ4 ambiguity, rather than quoting one blended purity figure.

For laboratory and research use only (RUO). Not for human or veterinary use, not for consumption, and not a medicine. Information is a research summary, not medical advice, and contains no dosing guidance.

For laboratory research use only. Not for human or veterinary use, not for consumption, and not a medicine. This is a research summary, not medical advice, and contains no dosing guidance.